Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Interstitial lung disease? 74 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 74 reports of Interstitial lung disease have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 0.8% of all adverse event reports for BRENTUXIMAB VEDOTIN.

74
Reports of Interstitial lung disease with BRENTUXIMAB VEDOTIN
0.8%
of all BRENTUXIMAB VEDOTIN reports
18
Deaths
34
Hospitalizations

How Dangerous Is Interstitial lung disease From BRENTUXIMAB VEDOTIN?

Of the 74 reports, 18 (24.3%) resulted in death, 34 (45.9%) required hospitalization, and 3 (4.1%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for BRENTUXIMAB VEDOTIN.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Interstitial lung disease Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease BRENTUXIMAB VEDOTIN Demographics